Immuron LimitedASX: IMC

US DoD NMRC Reports Positive Response to Vaccine

· Issued by Immuron Limited

Filed with ASX · · 3 pages · English

Key Points • NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETEC • Immuron executes a Research Agreement with PCI Clinical Services to manufacture drug product • Two human phase II clinical trials to be conductedin 2021 by the US NMRC • One trial will focus ETEC infections • The second trial will focus on the ability of the hyperimmune product to protec

Immuron Limited on 6ix

Story so far

Earlier from Immuron

Later from Immuron

All Immuron news releases